Canada markets closed

SOPHiA GENETICS SA (SOPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6600-0.0500 (-1.06%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.7100
Open4.7100
Bid4.6400 x 200
Ask4.7300 x 400
Day's Range4.5900 - 4.8000
52 Week Range2.1300 - 7.3700
Volume28,475
Avg. Volume105,038
Market Cap304.648M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    India-Based Dhiti Omics is Now Live on SOPHiA DDM™

    SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities.

  • GlobeNewswire

    SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting

    Shareholders adopt all proposals at Annual General MeetingBOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the “AGM”) was held at the Company’s headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT). The Company’s shareholders have adopted all proposals presented

  • PR Newswire

    SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

    SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.